These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 9589652)

  • 1. Effects of chronic growth hormone treatment on energy intake and resting energy metabolism in patients with human immunodeficiency virus-associated wasting--a clinical research center study.
    Mulligan K; Tai VW; Schambelan M
    J Clin Endocrinol Metab; 1998 May; 83(5):1542-7. PubMed ID: 9589652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic effects of biosynthetic growth hormone treatment in severely energy-restricted obese women.
    Tagliaferri M; Scacchi M; Pincelli AI; Berselli ME; Silvestri P; Montesano A; Ortolani S; Dubini A; Cavagnini F
    Int J Obes Relat Metab Disord; 1998 Sep; 22(9):836-41. PubMed ID: 9756240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection.
    Mulligan K; Grunfeld C; Hellerstein MK; Neese RA; Schambelan M
    J Clin Endocrinol Metab; 1993 Oct; 77(4):956-62. PubMed ID: 8408471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of body composition assessment methods in patients with human immunodeficiency virus-associated wasting receiving growth hormone.
    Esposito JG; Thomas SG; Kingdon L; Ezzat S
    J Clin Endocrinol Metab; 2006 Aug; 91(8):2952-9. PubMed ID: 16757527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. A randomized, double-blind, placebo-controlled trial.
    Waters D; Danska J; Hardy K; Koster F; Qualls C; Nickell D; Nightingale S; Gesundheit N; Watson D; Schade D
    Ann Intern Med; 1996 Dec; 125(11):865-72. PubMed ID: 8967666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment.
    Storer TW; Woodhouse LJ; Sattler F; Singh AB; Schroeder ET; Beck K; Padero M; Mac P; Yarasheski KE; Geurts P; Willemsen A; Harms MK; Bhasin S
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4474-82. PubMed ID: 15914526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group.
    Schambelan M; Mulligan K; Grunfeld C; Daar ES; LaMarca A; Kotler DP; Wang J; Bozzette SA; Breitmeyer JB
    Ann Intern Med; 1996 Dec; 125(11):873-82. PubMed ID: 8967667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial.
    Mulligan K; Zackin R; Von Roenn JH; Chesney MA; Egorin MJ; Sattler FR; Benson CA; Liu T; Umbleja T; Shriver S; Auchus RJ; Schambelan M;
    J Clin Endocrinol Metab; 2007 Feb; 92(2):563-70. PubMed ID: 17090640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.
    Hansen TB; Gram J; Jensen PB; Kristiansen JH; Ekelund B; Christiansen JS; Pedersen FB
    Clin Nephrol; 2000 Feb; 53(2):99-107. PubMed ID: 10711411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone treatment improves peripheral muscle oxygen extraction-utilization during exercise in patients with human immunodeficiency virus-associated wasting: a randomized controlled trial.
    Esposito JG; Thomas SG; Kingdon L; Ezzat S
    J Clin Endocrinol Metab; 2004 Oct; 89(10):5124-31. PubMed ID: 15472216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resting energy expenditure per lean body mass determined by indirect calorimetry and bioelectrical impedance analysis in cats.
    Center SA; Warner KL; Randolph JF; Wakshlag JJ; Sunvold GD
    J Vet Intern Med; 2011; 25(6):1341-50. PubMed ID: 22092626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anabolic growth hormone action improves submaximal measures of physical performance in patients with HIV-associated wasting.
    Esposito JG; Thomas SG; Kingdon L; Ezzat S
    Am J Physiol Endocrinol Metab; 2005 Sep; 289(3):E494-503. PubMed ID: 15886228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy.
    Moyle GJ; Daar ES; Gertner JM; Kotler DP; Melchior JC; O'brien F; Svanberg E;
    J Acquir Immune Defic Syndr; 2004 Apr; 35(4):367-75. PubMed ID: 15097153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of growth hormone and other anabolic agents in AIDS wasting.
    Mulligan K; Tai VW; Schambelan M
    JPEN J Parenter Enteral Nutr; 1999; 23(6 Suppl):S202-9. PubMed ID: 10571456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome.
    Kosmiski LA; Kuritzkes DR; Sharp TA; Hamilton JT; Lichtenstein KA; Mosca CL; Grunwald GK; Eckel RH; Hill JO
    Metabolism; 2003 May; 52(5):620-5. PubMed ID: 12759894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Energy expenditure, substrate oxidation, and body composition in subjects with chronic alcoholism: new findings from metabolic assessment.
    Addolorato G; Capristo E; Greco AV; Stefanini GF; Gasbarrini G
    Alcohol Clin Exp Res; 1997 Sep; 21(6):962-7. PubMed ID: 9309302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxymetholone for the treatment of HIV-wasting: a double-blind, randomized, placebo-controlled phase III trial in eugonadal men and women.
    Hengge UR; Stocks K; Faulkner S; Wiehler H; Lorenz C; Jentzen W; Hengge D; Ringham G
    HIV Clin Trials; 2003; 4(3):150-63. PubMed ID: 12815555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between GH-induced metabolic changes and changes in body composition: a dose and time course study in GH-deficient adults.
    Burt MG; Gibney J; Hoffman DM; Umpleby AM; Ho KK
    Growth Horm IGF Res; 2008 Feb; 18(1):55-64. PubMed ID: 17714967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment.
    Gelato M; McNurlan M; Freedland E
    Clin Ther; 2007 Nov; 29(11):2269-88. PubMed ID: 18158071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial.
    Strawford A; Barbieri T; Van Loan M; Parks E; Catlin D; Barton N; Neese R; Christiansen M; King J; Hellerstein MK
    JAMA; 1999 Apr; 281(14):1282-90. PubMed ID: 10208143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.